Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A. Francis, Gini F. Fleming, István Láng, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 7, pp. 1370-1375
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
Soo Yeon Baek, Woo Chul Noh, Sei‐Hyun Ahn, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 31, pp. 4864-4871
Closed Access | Times Cited: 28
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Stephen J. Luen, Giuseppe Viale, Serena Nik‐Zainal, et al.
Annals of Oncology (2023) Vol. 34, Iss. 4, pp. 397-409
Open Access | Times Cited: 26
Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
Tamer Al-Batsh, Nayef Abdel-Razeq, Yosra Al-Masri, et al.
Biologics (2025) Vol. Volume 19, pp. 97-111
Open Access | Times Cited: 1
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Kelly McCann, Shari Goldfarb, Tiffany A. Traina, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
Michael Untch, David Pérol, Erica L. Mayer, et al.
European Journal of Cancer (2024) Vol. 202, pp. 113977-113977
Closed Access | Times Cited: 6
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
Henning Schäffler, Franziska Mergel, Kerstin Pfister, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16366-16366
Open Access | Times Cited: 15
Ovarian Suppression: Early Menopause and Late Effects
Chiara Molinelli, Flavia Jacobs, Guilherme Nader Marta, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 4, pp. 523-542
Open Access | Times Cited: 5
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer
Erika Hamilton, S. Loibl, Thomas Bachelot, et al.
Future Oncology (2025), pp. 1-12
Open Access
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
Joyce O’Shaughnessy, Sara M. Tolaney, Denise A. Yardley, et al.
The Breast (2025), pp. 104437-104437
Open Access
Real-World Utilization of Aromatase Inhibitors, Tamoxifen, and Ovarian Function Suppression in Premenopausal Patients with Early Hormone Receptor-Positive, HER2-Negative Breast Cancer with Increased Recurrence Risk
Volkmar Müller, Manuel Hörner, Marc Thill, et al.
The Breast (2025), pp. 104458-104458
Open Access
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
Harsh Vardhan Batra, Jason Mouabbi, Qingqing Ding, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5491-5491
Open Access | Times Cited: 12
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Luca Cantini, Dario Trapani, Lorenzo Guidi, et al.
Cancer Treatment Reviews (2023) Vol. 123, pp. 102669-102669
Closed Access | Times Cited: 11
Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics
Bandari BharathwajChetty, Anjana Sajeev, Ravichandran Vishwa, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 321-362
Closed Access | Times Cited: 4
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
Adriano Gravina, P. Gargiulo, Michelino De Laurentiis, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104085-104085
Closed Access
Comparison of Oncological Outcomes of Premenopausal with Ovarian Function Suppression Versus Postmenopausal Women in Er+/Her2- Breast Cancer
Min Jung Lee, Ji-Jung Jung, Jong-Ho Cheun, et al.
(2025)
Closed Access
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
Andri Papakonstantinou, Guillermo Villacampa, Vı́ctor Navarro, et al.
EClinicalMedicine (2025) Vol. 81, pp. 103116-103116
Open Access
Comparison of Oncological Outcomes of Premenopausal with Ovarian Function Suppression versus Postmenopausal Women in ER+/HER2- Breast Cancer
Min Jung Lee, Ji-Jung Jung, Jong-Ho Cheun, et al.
The Breast (2025), pp. 104449-104449
Open Access
Overexpression of KIF2C amplifies tamoxifen resistance and lung metastasis of breast cancer through PLK1/C-Myc pathway
Rui Tian, Jilin Kong, Hongyan Zang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes
Linxiaoxi Ma, Benlong Yang, Jiong Wu
Cancer Treatment Reviews (2024) Vol. 129, pp. 102770-102770
Open Access | Times Cited: 3
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up
Jie Ju, Songlin Gao, Jiayu Wang, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 6, pp. 439-447
Open Access | Times Cited: 2
Tata Memorial Centre Evidence Based Management of Breast cancer
Tabassum Wadasadawala, Shalaka Joshi, Sushmita Rath, et al.
Indian Journal of Cancer (2024) Vol. 61, Iss. Suppl 1, pp. S52-S79
Open Access | Times Cited: 2
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
Ruth O’Regan, Yi Zhang, Gini F. Fleming, et al.
JAMA Oncology (2024) Vol. 10, Iss. 10, pp. 1379-1379
Closed Access | Times Cited: 2
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
Helena Record, Elle Clelland, Harriet Rothschild, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 5
A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer
Hunan Ye, Guang Lin, Xiaojia Wang
Translational Breast Cancer Research (2024) Vol. 5, pp. 20-20
Open Access | Times Cited: 1
ASCO 2023: highlights in breast cancer
Rupert Bartsch
memo - Magazine of European Medical Oncology (2023) Vol. 17, Iss. 2, pp. 96-99
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top